B4GALT5 (beta-1,4-galactosyltransferase 5) is a Golgi-localized enzyme that catalyzes the synthesis of lactosylceramide (LacCer) from glucosylceramide (GlcCer) and UDP-galactose 1. This enzymatic activity is essential for glycosphingolipid metabolism, as LacCer serves as a precursor for complex gangliosides important in neuronal function 2. B4GALT5 shows selective importance in immune cell biology, being required for natural killer cell generation and CD8+ T cell expansion during viral infections through its role in cytotoxic granule integrity 2. The enzyme is subject to mannose 6-phosphate tagging and GOLPH3/GOLPH3L-mediated Golgi localization, suggesting regulation through lysosomal degradation pathways 3. In disease contexts, B4GALT5 exhibits oncogenic properties, promoting tumor cell immune evasion by suppressing MHC-I expression in pancreatic cancer 4 and correlating with poor prognosis in hepatocellular carcinoma and ovarian cancer 56. Additionally, B4GALT5 downregulation during acute kidney injury contributes to GlcCer accumulation and inflammatory responses 7, while its interaction with UGCG influences cardiac hypertrophy through mitochondrial oxidative stress 8.